Clinical Trials Directory

Trials / Unknown

UnknownNCT05919524

SBRT With Focal Dose Escalation on DIL in Localized Prostate Cancer

Fractionated Stereotactic Ablative Body Radiotherapy (SBRT) With FOcal Dose Escalation on Dominant Lesion in Localized Prostate Cancer

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
27 (estimated)
Sponsor
Almudena Zapatero · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

Stereotactic ablative Body Radiotherapy (SBRT) is an advanced radiation technique that allows for precise delivery of higher radiation doses in fewer treatment sessions, resulting in a shorter overall treatment duration. The available clinical evidence suggests that SBRT is highly effective in controlling localized prostate cancer (PCa) with acceptable side effects. On the other side, dose escalation is a commonly employed strategy in radiotherapy for prostate cancer. Recent studies have confirmed a dose-response relationship, demonstrating improved biochemical control with focal dose escalation to the identified dominant intraprostatic lesion (DIL) on multiparametric magnetic resonance imaging (mpMRI) of the prostate. The hypothesis of this study is that the combination prostate SBRT with focal dose intensification on the DIL with preservation of the prostatic urethra, would lead to a higher probability of local control without a significant increase in toxicity compared to standard clinical practice. This is a prospective single-arm phase II study designed to evaluate the effectiveness, safety and impact on quality of life of focal dose intensification using SBRT technology and extreme hypofractionated radiotherapy.

Conditions

Interventions

TypeNameDescription
RADIATIONProstate SBRT (stereotactic body radiation therapy) with focal boost* Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions of 7.25 Gy to the entire prostate (including seminal vesicles) using VMAT * mpMRI defined DIL was simultaneously boosted up to 50 Gy in 5 sessions to the mpMRI identified DIL. * Additional urethra and bladder trigone sparing constrains * Daily IGRT with cone beam CT and intrafraction gold-seeds fiducial tracking

Timeline

Start date
2023-08-01
Primary completion
2024-07-01
Completion
2025-06-30
First posted
2023-06-26
Last updated
2023-09-26

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT05919524. Inclusion in this directory is not an endorsement.